[go: up one dir, main page]

WO2004065626A3 - Procede permettant de pronostiquer une sepsie - Google Patents

Procede permettant de pronostiquer une sepsie Download PDF

Info

Publication number
WO2004065626A3
WO2004065626A3 PCT/DK2004/000027 DK2004000027W WO2004065626A3 WO 2004065626 A3 WO2004065626 A3 WO 2004065626A3 DK 2004000027 W DK2004000027 W DK 2004000027W WO 2004065626 A3 WO2004065626 A3 WO 2004065626A3
Authority
WO
WIPO (PCT)
Prior art keywords
mbl
genotype
risk
sirs
sepsis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2004/000027
Other languages
English (en)
Other versions
WO2004065626A2 (fr
Inventor
Peter Garred
Hans Ole Madsen
Jens Stroem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigshospitalet
Original Assignee
Rigshospitalet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigshospitalet filed Critical Rigshospitalet
Publication of WO2004065626A2 publication Critical patent/WO2004065626A2/fr
Publication of WO2004065626A3 publication Critical patent/WO2004065626A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention se rapporte à un procédé destiné à prédire si une personne atteinte du syndrome de réponse inflammatoire systémique (SRIS) contractera une sepsie, et ce par la mise en corrélation du génotype MBL avec une estimation du risque prédéfinie associée au génotype MBL en question. Dans le présent contexte, une estimation du risque prédéfinie associée au génotype MBL en question peut se diviser en un risque élevé et un risque faible que ladite personne atteinte du SRIS contracte une sepsie. En général, un génotype MBL présentant un risque élevé est caractérisé en ce qu'il possède au moins un allèle structurel variant du gène MBL et/ou possédant deux allèles régulateurs à faible expression du gène MBL dans les échantillons prélevés.
PCT/DK2004/000027 2003-01-17 2004-01-16 Procede permettant de pronostiquer une sepsie Ceased WO2004065626A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200300042 2003-01-17
DKPA200300042 2003-01-17
US45327203P 2003-03-06 2003-03-06
US60/453,272 2003-03-06

Publications (2)

Publication Number Publication Date
WO2004065626A2 WO2004065626A2 (fr) 2004-08-05
WO2004065626A3 true WO2004065626A3 (fr) 2004-09-10

Family

ID=32773405

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2004/000027 Ceased WO2004065626A2 (fr) 2003-01-17 2004-01-16 Procede permettant de pronostiquer une sepsie

Country Status (1)

Country Link
WO (1) WO2004065626A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008107377A2 (fr) * 2007-03-02 2008-09-12 Innogenetics N.V. Combinaisons de marqueurs de l'évaluation du risque de septicémie
CA2740191A1 (fr) * 2008-10-09 2010-04-15 Thomas Ryan Procede d'estimation du risque de sepsie chez un individu ayant une infection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010014449A1 (en) * 1993-11-01 2001-08-16 Michael I. Nerenberg Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip
WO2002005833A1 (fr) * 2000-07-13 2002-01-24 Natimmune A/S Traitement a la lectine de liaison au mannane d'infections chez les personnes traitees avec des inhibiteurs de tnf-$g(a)
WO2002006460A2 (fr) * 2000-07-13 2002-01-24 Jens Christian Jensenius Masp-2, enzyme de fixation de complements et ses utilisations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010014449A1 (en) * 1993-11-01 2001-08-16 Michael I. Nerenberg Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip
WO2002005833A1 (fr) * 2000-07-13 2002-01-24 Natimmune A/S Traitement a la lectine de liaison au mannane d'infections chez les personnes traitees avec des inhibiteurs de tnf-$g(a)
WO2002006460A2 (fr) * 2000-07-13 2002-01-24 Jens Christian Jensenius Masp-2, enzyme de fixation de complements et ses utilisations

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
MADSEN H ET AL: "Different molecular events result in low protein levels of mannan-lectin in populations from Southeast africa and South America", JOURNAL OF IMMUNOLOGY, vol. 161, no. 6, 1998, pages 3169 - 78, XP001159170 *
MULLIGHAN C ET AL: "Mannose-binding lectin gene polymorphisms are associated with major infection following allogenic hemopoietic stem cell transplantation", BLOOD, vol. 99, no. 10, 15 May 2002 (2002-05-15), pages 3524 - 29, XP002246417 *
STEFFENSEN R ET AL: "Detection of structural gene mutations and promoter polymorphisms in the mannan-binding lectin (MBL) gene by polymerase chain reaction with sequence-specific primers", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 241, no. 1-2, 31 July 2000 (2000-07-31), pages 33 - 42, XP004213709, ISSN: 0022-1759 *
TAKAHASHI K ET AL: "Lack of mannose-binding lectin-A enhances survival in a mouse model of acute septic peritonitis", MICROBES AND INFECTION, vol. 4, 2002, pages 773 - 84, XP002246419 *
THIEL S ET AL: "Plasma level of mannan-binding lectin (MBL) as predictor of sepsis after chemotherapy", IMMUNOPHARMACOLOGY, vol. 49, no. 1-2, August 2000 (2000-08-01), pages 85, XP008018674 *

Also Published As

Publication number Publication date
WO2004065626A2 (fr) 2004-08-05

Similar Documents

Publication Publication Date Title
Eriksson et al. Extended exome sequencing identifies BACH2 as a novel major risk locus for Addison's disease
WO2007019269A3 (fr) Systeme et procede permettant de creer un modele de focalisation-exposition d'un processus lithographique
WO2004046098A3 (fr) Technique de prevision de maladies auto-immunes
WO2008109075A3 (fr) Biomarqueurs et procédés pour déterminer une sensibilité à des antagonistes de ctla-4
WO2005081867A3 (fr) Profilage de l'arnm salivaire, biomarqueurs et methodes et trousses de parties
AU2016216744A1 (en) Novel Biomarkers
WO2008060651A8 (fr) Sparc et procédés d'utilisation de celui-ci
WO2008048119A3 (fr) Procédés d'analyse des polymorphismes, et utilisations
WO2009006347A3 (fr) Procédés et compositions pour le diagnostic et/ou le pronostic dans des syndromes de réponse inflammatoire systémique
WO2005017646A3 (fr) Système, logiciel et procédés pour l'identification de biomarqueurs
WO2008134526A3 (fr) Profilage de glycoprotéines du cancer de la vessie
ATE373239T1 (de) Serum macrophage migration inhibitory factor (mif) als marker für prostata krebs
WO2010061283A3 (fr) Biomarqueurs pour diagnostiquer et détecter la progression de troubles neurodégénératifs, en particulier de la sclérose latérale amyotrophique
WO2004108948A3 (fr) Systemes, procedes et trousses permettant de caracteriser les phosphoproteomes
WO2005028674A3 (fr) Procede et kits utilises pour detecter une modification dans le nombre de copies d'un locus
PT2185937E (pt) Método para ensaiar septicemia em seres humanos
WO2018060739A3 (fr) Dosage pour distinguer un sepsis d'un syndrome de réponse inflammatoire systémique
EP3745132A3 (fr) Détection de la septicémie
HK1259478A1 (zh) 用於检测异常核型的方法和系统
WO2006129131A3 (fr) Biomarqueurs
WO2008042572A3 (fr) Procédé et système permettant de faciliter une maintenance préventive d'un outil d'inspection optique
WO2004065626A3 (fr) Procede permettant de pronostiquer une sepsie
EA200970256A1 (ru) Биомаркеры для определения функции печени
DK1887359T3 (da) Fremgangsmåde til identifikation af PI3K-interagerende molekyler og til rensning af PI3K
Pöge et al. Prediction of glomerular filtration rate in renal transplant recipients: cystatin C or modification of diet in renal disease equation?

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase